VR Adviser LLC grew its position in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 41.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,046,414 shares of the company's stock after purchasing an additional 1,480,573 shares during the period. enGene comprises about 2.3% of VR Adviser LLC's holdings, making the stock its 16th largest position. VR Adviser LLC owned approximately 11.41% of enGene worth $33,559,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Fcpm Iii Services B.V. increased its position in enGene by 11.0% in the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock worth $64,057,000 after purchasing an additional 954,610 shares during the last quarter. Deep Track Capital LP increased its holdings in shares of enGene by 74.8% during the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock valued at $30,308,000 after acquiring an additional 1,949,942 shares during the last quarter. Blue Owl Capital Holdings LP increased its holdings in shares of enGene by 3.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock valued at $21,014,000 after acquiring an additional 101,006 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of enGene by 84.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company's stock valued at $8,145,000 after acquiring an additional 561,797 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of enGene during the 4th quarter valued at about $6,120,000. 64.16% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Morgan Stanley lowered their price objective on enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. UBS Group lowered enGene from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $34.00 to $7.00 in a report on Friday, February 14th. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of enGene in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of enGene in a report on Tuesday, March 11th. Finally, Piper Sandler assumed coverage on enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $23.29.
Read Our Latest Research Report on enGene
enGene Stock Performance
ENGN opened at $3.91 on Tuesday. The firm has a market capitalization of $199.32 million, a P/E ratio of -6.74 and a beta of -0.36. The stock's 50 day moving average price is $4.15 and its two-hundred day moving average price is $6.02. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene Holdings Inc. has a 12-month low of $2.65 and a 12-month high of $13.28.
About enGene
(
Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
